Emily P. Van Syoc , Janhavi Damani , Zachary DiMattia , Erika Ganda , Connie J. Rogers
{"title":"补充双歧杆菌益生菌对血糖的影响:临床前动物模型和临床证据的系统综述和荟萃分析。","authors":"Emily P. Van Syoc , Janhavi Damani , Zachary DiMattia , Erika Ganda , Connie J. Rogers","doi":"10.1016/j.advnut.2023.10.009","DOIUrl":null,"url":null,"abstract":"<div><p>Probiotic supplementation is a potential therapeutic for metabolic diseases, including obesity, metabolic syndrome (MetS), and type 2 diabetes (T2D), but most studies deliver multiple species of bacteria in addition to prebiotics or oral pharmaceuticals. This may contribute to conflicting evidence in existing meta-analyses of probiotics in these populations and warrants a systematic review of the literature to assess the contribution of a single probiotic genus to better understand the contribution of individual probiotics to modulate blood glucose. We conducted a systematic review and meta-analysis of animal studies and human randomized controlled trials (RCTs) to assess the effects of <em>Bifidobacterium</em> (<em>BF</em>) probiotic supplementation on markers of glycemia. In a meta-analysis of 6 RCTs, <em>BF</em> supplementation had no effect on fasting blood glucose {FBG; mean difference [MD] = −1.99 mg/dL [95% confidence interval (CI): −4.84, 0.86], <em>P</em> = 0.13}, and there were no subgroup differences between subjects with elevated FBG concentrations and normoglycemia. However, <em>BF</em> supplementation reduced FBG concentrations in a meta-analysis comprised of studies utilizing animal models of obesity, MetS, or T2D [<em>n =</em> 16; MD = −36.11 mg/dL (CI: −49.04, −23.18), <em>P</em> < 0.0001]. Translational gaps from animal to human trials include paucity of research in female animals, <em>BF</em> supplementation in subjects that were normoglycemic, and lack of methodologic reporting regarding probiotic viability and stability. More research is necessary to assess the effects of <em>BF</em> supplementation in human subjects with elevated FBG concentrations. Overall, there was consistent evidence of the efficacy of <em>BF</em> probiotics to reduce elevated FBG concentrations in animal models but not clinical trials, suggesting that <em>BF</em> alone may have minimal effects on glycemic control, may be more effective when combined with multiple probiotic species, or may be more effective in conditions of hyperglycemia rather than elevated FBG concentrations.</p></div>","PeriodicalId":7349,"journal":{"name":"Advances in Nutrition","volume":null,"pages":null},"PeriodicalIF":8.0000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2161831323013984/pdfft?md5=864e5955206d5fa6da355e38ca2d7f27&pid=1-s2.0-S2161831323013984-main.pdf","citationCount":"0","resultStr":"{\"title\":\"The Effects of Bifidobacterium Probiotic Supplementation on Blood Glucose: A Systematic Review and Meta-Analysis of Animal Models and Clinical Evidence\",\"authors\":\"Emily P. Van Syoc , Janhavi Damani , Zachary DiMattia , Erika Ganda , Connie J. Rogers\",\"doi\":\"10.1016/j.advnut.2023.10.009\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>Probiotic supplementation is a potential therapeutic for metabolic diseases, including obesity, metabolic syndrome (MetS), and type 2 diabetes (T2D), but most studies deliver multiple species of bacteria in addition to prebiotics or oral pharmaceuticals. This may contribute to conflicting evidence in existing meta-analyses of probiotics in these populations and warrants a systematic review of the literature to assess the contribution of a single probiotic genus to better understand the contribution of individual probiotics to modulate blood glucose. We conducted a systematic review and meta-analysis of animal studies and human randomized controlled trials (RCTs) to assess the effects of <em>Bifidobacterium</em> (<em>BF</em>) probiotic supplementation on markers of glycemia. In a meta-analysis of 6 RCTs, <em>BF</em> supplementation had no effect on fasting blood glucose {FBG; mean difference [MD] = −1.99 mg/dL [95% confidence interval (CI): −4.84, 0.86], <em>P</em> = 0.13}, and there were no subgroup differences between subjects with elevated FBG concentrations and normoglycemia. However, <em>BF</em> supplementation reduced FBG concentrations in a meta-analysis comprised of studies utilizing animal models of obesity, MetS, or T2D [<em>n =</em> 16; MD = −36.11 mg/dL (CI: −49.04, −23.18), <em>P</em> < 0.0001]. Translational gaps from animal to human trials include paucity of research in female animals, <em>BF</em> supplementation in subjects that were normoglycemic, and lack of methodologic reporting regarding probiotic viability and stability. More research is necessary to assess the effects of <em>BF</em> supplementation in human subjects with elevated FBG concentrations. Overall, there was consistent evidence of the efficacy of <em>BF</em> probiotics to reduce elevated FBG concentrations in animal models but not clinical trials, suggesting that <em>BF</em> alone may have minimal effects on glycemic control, may be more effective when combined with multiple probiotic species, or may be more effective in conditions of hyperglycemia rather than elevated FBG concentrations.</p></div>\",\"PeriodicalId\":7349,\"journal\":{\"name\":\"Advances in Nutrition\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":8.0000,\"publicationDate\":\"2024-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.sciencedirect.com/science/article/pii/S2161831323013984/pdfft?md5=864e5955206d5fa6da355e38ca2d7f27&pid=1-s2.0-S2161831323013984-main.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Advances in Nutrition\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2161831323013984\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"NUTRITION & DIETETICS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advances in Nutrition","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2161831323013984","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"NUTRITION & DIETETICS","Score":null,"Total":0}
The Effects of Bifidobacterium Probiotic Supplementation on Blood Glucose: A Systematic Review and Meta-Analysis of Animal Models and Clinical Evidence
Probiotic supplementation is a potential therapeutic for metabolic diseases, including obesity, metabolic syndrome (MetS), and type 2 diabetes (T2D), but most studies deliver multiple species of bacteria in addition to prebiotics or oral pharmaceuticals. This may contribute to conflicting evidence in existing meta-analyses of probiotics in these populations and warrants a systematic review of the literature to assess the contribution of a single probiotic genus to better understand the contribution of individual probiotics to modulate blood glucose. We conducted a systematic review and meta-analysis of animal studies and human randomized controlled trials (RCTs) to assess the effects of Bifidobacterium (BF) probiotic supplementation on markers of glycemia. In a meta-analysis of 6 RCTs, BF supplementation had no effect on fasting blood glucose {FBG; mean difference [MD] = −1.99 mg/dL [95% confidence interval (CI): −4.84, 0.86], P = 0.13}, and there were no subgroup differences between subjects with elevated FBG concentrations and normoglycemia. However, BF supplementation reduced FBG concentrations in a meta-analysis comprised of studies utilizing animal models of obesity, MetS, or T2D [n = 16; MD = −36.11 mg/dL (CI: −49.04, −23.18), P < 0.0001]. Translational gaps from animal to human trials include paucity of research in female animals, BF supplementation in subjects that were normoglycemic, and lack of methodologic reporting regarding probiotic viability and stability. More research is necessary to assess the effects of BF supplementation in human subjects with elevated FBG concentrations. Overall, there was consistent evidence of the efficacy of BF probiotics to reduce elevated FBG concentrations in animal models but not clinical trials, suggesting that BF alone may have minimal effects on glycemic control, may be more effective when combined with multiple probiotic species, or may be more effective in conditions of hyperglycemia rather than elevated FBG concentrations.
期刊介绍:
Advances in Nutrition (AN/Adv Nutr) publishes focused reviews on pivotal findings and recent research across all domains relevant to nutritional scientists and biomedical researchers. This encompasses nutrition-related research spanning biochemical, molecular, and genetic studies using experimental animal models, domestic animals, and human subjects. The journal also emphasizes clinical nutrition, epidemiology and public health, and nutrition education. Review articles concentrate on recent progress rather than broad historical developments.
In addition to review articles, AN includes Perspectives, Letters to the Editor, and supplements. Supplement proposals require pre-approval by the editor before submission. The journal features reports and position papers from the American Society for Nutrition, summaries of major government and foundation reports, and Nutrient Information briefs providing crucial details about dietary requirements, food sources, deficiencies, and other essential nutrient information. All submissions with scientific content undergo peer review by the Editors or their designees prior to acceptance for publication.